Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brexit: MHRA Joins Second International Work-Sharing Scheme To Speed Up Drug Approvals

Executive Summary

Hot on the heels of announcing it was joining Project Orbis, the UK drug regulator, the MHRA, now says it will join another international collaboration that allows drug companies to submit medicines for review by several countries at the same time.

You may also be interested in...



Brexit: UK Joining US-Led Project Orbis To Speed Cancer Drug Approvals

Joining the international regulatory collaboration could become a key route for the UK to remain an early and priority market for global launches after the end of the Brexit transition period, says the industry group, BIA.

Hat Trick For Xofluza As Canadian, Swiss & Australian Regulators Join Forces

Xofluza is also the first non-cancer drug to be reviewed under the Australia-Canada-Singapore-Switzerland (ACSS) Consortium’s work-sharing initiative.

Incoming EMA Chief Throws Weight Behind Antimicrobial Resistance Fight

Antimicrobial resistance, the lack of new antibiotics, and preserving the effectiveness of existing ones are high on the agenda for the soon-to-be new head of the European Medicines Agency, Emer Cooke.

Topics

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel